(Date:11/25/2009)...ness could lead mothers to overlook needed care, s...hDay News) -- A mother,s depression can worsen her... Their six-month study of 262 black mothers and th... more depressive symptoms had more frequent asthma...pressive symptoms had less frequent asthma symptom...
(Date:11/25/2009)...v.25/PRNewswire/-- MISSIONSkincare ®isproudto...ude.AspartofGNC,sannualSt.Jude ThanksandGiving cam...e,s new SUPER-C(TM)LipBalm willbedonatedtoSt.Jud...ea$1,$5or$10donationatcheckoutatoneoftheir5,000+re...millionforSt.Judeduringtheir2009 ThanksandGiving c...
(Date:11/25/2009)... -- A cancer vaccine carried into the body on a ca...e first to successfully eliminate tumors in mammal...ence Translational Medicine . , The new approach...arvard University, uses plastic disks impregnated ...he skin to reprogram the mammalian immune system t...
(Date:11/25/2009)...ced under the skin kill tumor cells, study finds ,...- A cancer vaccine delivered in a fingernail-size ...study reports. , The method uses polymer disks,... tumor-specific antigens and implanted under the s...s. The Harvard University scientists who developed...
(Date:11/25/2009)... Initiative expands to include cost-effecti...achers, and healthcare professionals in developing...(PRWEB) November 25, 2009 -- Elluminate, Inc. , t...ing solutions that support 21st century teaching,... its Fire and Ice initiative was awarded iNACOL...
Breaking Medicine News(10 mins):Health News:Mom's Depression May Worsen Child's Asthma 2Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 4Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 5...to a New Jersey Hospital, RIDGEWOOD, N.J., June 1...ader and well-known community philanthropist,has p...Valley Hospital in,Ridgewood, NJ. The gift of $30 ...his gift to Valley because I want my giving to do ...
...d nonprofit Los Angeles,Jewish Home announced toda...ess program designed to address one of the major h...funded by the Jewish Community Foundation,the larg...care,the Home provides to all its residents and in...
...therapy in the treatment of bowel cancer can enhan...onal therapies. The technique has managed to apply...l volume and risk areas, while minimising irradiat...conventional ones. In this way the treatment time ...
...d deaths, the gap between black and white American...archers at the Johns Hopkins Bloomberg School of P...d 2005 injury-related deaths among blacks ages 15 ..."Between the years of 1999 and 2005 the injury mor...
... Event, held recently in Cancun, Mexico, attracte...nada - who are, looking to retire overseas. Reason...ess to quality health care and a lower cost of liv...on,t make mistakes. That was the premise of the,In...
...ical Enterprises,Inc.), a privately held medical d...ry implant technology, today announced the launch ...nt designed for internal fixation of,bone., The B...s shape when heated above body temperature to prov...
Other Medicine News:Health News:The Valley Hospital in Ridgewood, NJ, Announces Historic $30 Million Gift 2Health News:Los Angeles Jewish Home Institutes New Fall Prevention Program With Jewish Community Foundation Grant 2Health News:Los Angeles Jewish Home Institutes New Fall Prevention Program With Jewish Community Foundation Grant 3Health News:Modulated radiotherapy can cut treatment time for cancer of the rectum without increasing toxicity 2Health News:Racial disparities reduced in injury related mortality 2Health News:International Living Ultimate Event Attracts Nearly 300 Attendees Who Explore the Growing Trend of Retiring Overseas 2Health News:International Living Ultimate Event Attracts Nearly 300 Attendees Who Explore the Growing Trend of Retiring Overseas 3Health News:BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant 2(Date:11/25/2009)....,Nov.25/PRNewswire/--CempraPharmaceuticalsInc.tod...iefexecutiveofficer,willpresentatthePiperJaffray21...1,2009,atTheNewYorkPalaceHotelinNewYorkCity.Dr.Fer...gantibioticclinicalprogramsforthetreatmentofdrug-r...Pharmaceuticals ,, Foundedin2006,CempraPharmac...
(Date:11/25/2009)...alif.,Nov.25/PRNewswire/-- ChemoCentryx,Inc.,anno...y,sPROTECT-1(theProspectiveRandomizedOralTherapyEv...X282-B)inpatientswithmoderate-to-severeCrohn,sdise...yandtolerabilityprofile.Thestudydemonstratedeviden...yasdefinedasa70-pointdecreaseintheCrohn,sDiseaseAc...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--Vermillion,Inc.(VRM...nofReorganizationandDisclosureStatementtoday,Novem...eDistrictofDelaware.Ahearingtoconsiderapprovalofth...r8,2009,withthehearingontheconfirmationofthePlansc...ompanytopayallclaimsinfull.ThePlanisexpected,ifapp...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Sunesis Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 6012 1Sunesis Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 6012 2Sunesis Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 6012 3Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 1Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 2Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 3Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 4Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 5Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 6Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 7Amgen Announces Overall Survival Results for Vectibix 28R 29 in First Line Metastatic Colorectal Cancer 6010 8Competitive Technologies Selects RF 7CBinder as Public Relations Agency of Record 6008 1Competitive Technologies Selects RF 7CBinder as Public Relations Agency of Record 6008 2Competitive Technologies Selects RF 7CBinder as Public Relations Agency of Record 6008 3... increase in advanced non-small cell, lung cancer ...clitaxel and cisplat...include reductions in chemotherapy-indu...OKYO, March 18 BioNumerik,Pharmaceuticals, Inc. (...ASKA") today announced the results of a Phase III ...
... 2b in Second Quarter of 2008 - - Conferen... DIEGO, March 17 Ardea Biosciences, Inc.,(Nasdaq:...lts from its,ongoing Phase 2a proof-of-concept stu...oside reverse transcriptase inhibitor (NNRTI), in,... Preliminary results from the first two of three ...
Other Medicine Technology:BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM) 2BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM) 3BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM) 4BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM) 5Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 2Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 4UPJ Occlusion Balloon Catheter
Omega NV Balloon Ureteral Dilator Sets
AquaGuide Ureteral Access Sheath
Flexible Ureteroscopy Sheath Set
Medicine Products: